CERo TherapeuticsCERO
CERO
About: CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
0
Funds holding %
of 7,290 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
200% more capital invested
Capital invested by funds: $318K [Q3] → $956K (+$638K) [Q4]
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
18% more funds holding
Funds holding: 17 [Q3] → 20 (+3) [Q4]
0.31% more ownership
Funds ownership: 6.64% [Q3] → 6.95% (+0.31%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for CERO.
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
CERo Therapeutics Holdings, Inc. Highlights Progress
Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025
Neutral
GlobeNewsWire
3 weeks ago
CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
SOUTH SAN FRANSCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced the pricing of its “reasonable best efforts” public offering with participation from a member of the Company's board and a single institutional investor for the purchase and sale of 2,551,020 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,551,020 shares of common stock at a combined purchase price of $1.96 (the “Offering”). The warrants will have an exercise price of $1.96 per share, will be immediately exercisable upon stockholder approval and will expire 5 years from the initial exercise date.
Neutral
GlobeNewsWire
2 months ago
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces its Board of Directors has appointed Chris Ehrlich as CEO. Previously he held the position of Interim CEO.
Neutral
GlobeNewsWire
3 months ago
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug Application (IND) for Phase 1 clinical trials of its lead compound, CER-1236, in acute myelogenous leukemia (AML).
Neutral
GlobeNewsWire
3 months ago
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in preclinical models with no indications of toxicity in animal models.
Neutral
GlobeNewsWire
4 months ago
CERo Therapeutics, Inc. Provides Corporate Update
Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides the following corporate update to stockholders from Interim CEO Chris Ehrlich.
Neutral
GlobeNewsWire
5 months ago
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces key appointments to the Company's management team to support recently named interim CEO, Chris Ehrlich. Andrew Albert “Al” Kucharchuk has been named Chief Financial Officer and Kristen Pierce, Ph.D., has been appointed Chief Development Officer.
Negative
Benzinga
5 months ago
Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones index falling over 200 points on Wednesday.
Neutral
GlobeNewsWire
5 months ago
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236
Company requests Type A Meeting with U.S. Food and Drug Administration regarding clinical hold for CER-1236; announces key management changes
Positive
Benzinga
7 months ago
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `
Charts implemented using Lightweight Charts™